Oxurion

Oxurion was founded in 1996 as ThromboGenics, a spin-off from the University of Leuven in Belgium. The company changed its name to Oxurion in 2018 to reflect its focus on ophthalmology. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA, and is listed on Euronext Brussels under the symbol OXUR.

Oxurion has a market cap of about 200 million euros as of May 2023. The company has a strong cash position of 70 million euros as of December 2022, which allows it to fund its clinical development programs and pursue strategic partnerships.

Oxurion's main product candidate is THR-149, a potent plasma kallikrein inhibitor for the treatment of DME. DME is a complication of diabetes that causes swelling and damage to the retina, leading to vision loss. Up to 50% of DME patients do not respond well to anti-VEGF therapies, the current standard of care. THR-149 has shown promising results in a phase 2 trial, improving vision and reducing retinal thickness in DME patients who are suboptimal responders to anti-VEGF therapy.

Oxurion has received several awards and recognitions for its scientific excellence and innovation. In 2020, Oxurion won the Belgian Biotech Award for Best Biotech Company. In 2021, Oxurion was selected as one of the Fierce 15 Biotech Companies by Fierce Biotech, a leading industry publication. In 2022, Oxurion was named as one of the Top 10 Ophthalmology Companies by Pharma Tech Outlook, a magazine that showcases the latest trends and innovations in the pharmaceutical industry.

Foundation: 1996

Headquarters: Leuven, Belgium

Website: https://oxurion.com/